Goodwin Advises Alpha Wave on Investment in Moonwalk Biosciences’ $70M Series B Financing Round

The Life Sciences, Technology, Healthcare, and Investment Funds and Capital teams advised Alpha Wave Ventures (“Alpha Wave”) on its investment in Moonwalk Biosciences, Inc., (“Moonwalk Biosciences”) in connection with its $70 million Series B financing round. The round was led by Alpha Wave and YK Bioventures, with participation from existing and new investors, including Eli Lilly and Gaorong. Proceeds will support advancement of Moonwalk’s lead obesity candidate, MW101, into first-in-human clinical studies in late 2027, expand the company’s pipeline of tissue-targeted siRNA medicines, and further advance its proprietary discovery platform.

Alpha Wave is a global growth equity firm based in New York, with offices in New York, Miami, London, Abu Dhabi, Tel Aviv, Bangalore, Jakarta, and Sydney. Alpha Wave aims to invest in best-in-class venture and growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. Alpha Wave manages a variety of investment partnerships that cover several asset classes, themes, and geographies.

Moonwalk Biosciences is a biotechnology company developing targeted siRNA therapies for obesity and related metabolic diseases. Its discovery platform combines human genetics, epigenetic analysis, and disease-relevant models to identify causal targets in adipose tissue, with preclinical programs designed to reduce fat mass while preserving lean mass.

The Goodwin team was led by Dan Lang, Micaiah Barley, and Erin Matsutsuyu (Corporate); Carl Morales, Yingying Cai, and Katherine Beck (IP); Alan Wang and Longfei Fang (Licensing); Matt Wetzel and Dustin Schaefer (Healthcare); Steve Tjoe (Regulatory); Justin Pierce, Nate William Cunningham, and Gozde “GG” Guckaya (Global Trade); and Janet Andolina (Tax), with invaluable assistance from Rob Intile.

For more information on the deal, please read the press release.